Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

Intelligence powered by the Humanexa engine.

Therapeutic Area

Lymphoma

Therapeutic area intelligence for Lymphoma with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Companies

ClinicalAugust 9, 2026

A Phase 1b trial is evaluating the safety and efficacy of Iberdomide (CC-220) and CC-99282 combined with R-CHOP for treating lymphoma.

ClinicalJuly 27, 2026

A new observational study aims to create a molecular and cellular atlas of MALT lymphoma to identify tumor subtypes and biomarkers.

ClinicalJuly 25, 2026

A study is underway comparing zanubrutinib plus obinutuzumab to lenalidomide plus rituximab in R/R follicular lymphoma and marginal zone lymphoma.

ClinicalJuly 2, 2026

A health services study will evaluate a multidisciplinary intervention program for fatigue in lymphoma patients.

No catalysts indexed for this entity yet.

Newsletter

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.